Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525

Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
  English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |   
l�ll Susceptibility testing of macrolide and lincosamide antibiotics according to DIN guidelines Deutsches Institut fur Normung Schmalreck AF; Kottmann I; Reiser A; Ruffer U; Schlenk R; Vanca E; Wildfeuer AJ Antimicrob Chemother 1997[Aug]; 40 (2): 179-87The in-vitro activity of azithromycin, clarithromycin, erythromycin, josamycin, midekamycin, roxithromycin and clindamycin against 674 Gram-negative and Gram-positive clinical isolates, including methicillin-resistant Staphylococcus aureus, was determined by agar dilution, microdilution and agar diffusion with Mueller-Hinton medium according to the Deutsches Institut fur Normung (DIN) 58940 guidelines. The results obtained by regression analysis and the error-rate-bounded method of Metzler-DeHaan indicate that common interpretative criteria (breakpoints) for test discs may be assigned to susceptible/resistant Gram-positive strains for all antibiotics tested. The following tentative DIN values are suggested for 15 microg macrolide discs: for susceptible Gram-positive and Gram-negative strains, an inhibition zone diameter (IZD) of > or = 26 mm at a corresponding MIC of < or = 2 mg/L; for resistant Gram-positive strains, an IZD of < or = 21 mm; for resistant Gram-negative strains, an IZD of < or = 19 mm at a corresponding MIC of > or = 8 mg/L. For Haemophilus influenzae only, breakpoints for azithromycin are suggested with IZDs of > or = 21 mm for susceptible and < or = 18 mm for resistant.|*Microbial Sensitivity Tests[MESH]|Anti-Bacterial Agents/*pharmacology[MESH]|Dose-Response Relationship, Drug[MESH]|Gram-Negative Bacteria/*drug effects[MESH]|Gram-Positive Bacteria/*drug effects[MESH]|Guidelines as Topic[MESH]|Haemophilus influenzae/drug effects[MESH]|Humans[MESH]|Lincosamides[MESH]|Macrolides/pharmacology[MESH]|Methicillin Resistance[MESH]|Staphylococcus aureus/drug effects[MESH] |